BIOMAT Database Logo BIOMAT Database Logo

Clinical and metabolic effects of pentaerythritol tetranicotinate in combination with cholesolvin or clofibrate. 1974

A G Olsson, and L Orö, and S Rössner

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008079 Lipoproteins, VLDL A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues. Pre-beta-Lipoprotein,Prebeta-Lipoprotein,Prebeta-Lipoproteins,Very Low Density Lipoprotein,Very-Low-Density Lipoprotein,Very-Low-Density Lipoproteins,Lipoprotein VLDL II,Lipoproteins, VLDL I,Lipoproteins, VLDL III,Lipoproteins, VLDL1,Lipoproteins, VLDL2,Lipoproteins, VLDL3,Pre-beta-Lipoproteins,Lipoprotein, Very-Low-Density,Lipoproteins, Very-Low-Density,Pre beta Lipoprotein,Pre beta Lipoproteins,Prebeta Lipoprotein,Prebeta Lipoproteins,VLDL Lipoproteins,VLDL1 Lipoproteins,VLDL2 Lipoproteins,VLDL3 Lipoproteins,Very Low Density Lipoproteins
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009539 Nicotinic Acids 2-, 3-, or 4-Pyridinecarboxylic acids. Pyridine derivatives substituted with a carboxy group at the 2-, 3-, or 4-position. The 3-carboxy derivative (NIACIN) is active as a vitamin. Acids, Nicotinic
D010647 Phenyl Ethers Ethers that are linked to a benzene ring structure. Diphenyl Oxide,Diphenyl Oxides,Diphenyl Ethers,Ethers, Diphenyl,Ethers, Phenyl,Oxide, Diphenyl,Oxides, Diphenyl
D011409 Propylene Glycols Derivatives of propylene glycol (1,2-propanediol). They are used as humectants and solvents in pharmaceutical preparations. Propanediols,Glycols, Propylene
D002087 Butyrates Derivatives of BUTYRIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxypropane structure. Butyrate,n-Butyrate,Butanoic Acids,Butyric Acids,Acids, Butanoic,Acids, Butyric,n Butyrate
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002994 Clofibrate A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) Athromidin,Atromid,Atromid S,Clofibric Acid, Ethyl Ester,Ethyl Chlorophenoxyisobutyrate,Miscleron,Miskleron,Chlorophenoxyisobutyrate, Ethyl

Related Publications

A G Olsson, and L Orö, and S Rössner
The behavior of pentaerythritol tetranicotinate in rat gastrointestinal tract as a prodrug.
February 1981, Journal of pharmacobio-dynamics,
A G Olsson, and L Orö, and S Rössner
Comparison between the absorption of nicotinic acid and pentaerythritol tetranicotinate (Perycit) from ordinary and enterocoated tablets.
January 1970, Acta pharmacologica et toxicologica,
A G Olsson, and L Orö, and S Rössner
The antilipemic effectiveness of pentaerythritol tetranicotinate on hyperlipidemic patients with or without diabetes mellitus--a double-blind, randomized and two-period change-over experiment.
January 1985, Proceedings of the National Science Council, Republic of China. Part B, Life sciences,
A G Olsson, and L Orö, and S Rössner
[Meso-inositol hexa-nicotinate (Hexanicit) and pentaerythritol tetranicotinate (Bufon) for restless legs. A controlled blind study].
August 1970, Ugeskrift for laeger,
A G Olsson, and L Orö, and S Rössner
Metabolic effects of clofibrate on experimental animals.
January 1978, Arzneimittel-Forschung,
A G Olsson, and L Orö, and S Rössner
Metabolic effects of prolonged ethanol administration in rats treated with clofibrate.
September 1976, Acta pharmacologica et toxicologica,
A G Olsson, and L Orö, and S Rössner
Comparison of plasma levels of free nicotinic acid in rats and rabbits treated with nicotinic acid, pentaerythritol tetranicotinate (Perycit) and 2,6-pyridine dimethanol dinicotinoate.
November 1978, Il Farmaco; edizione pratica,
A G Olsson, and L Orö, and S Rössner
Long term metabolic effects of enalapril alone or in combination with hydrochlorothiazide.
December 1987, Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences medicales et pharmacologiques,
A G Olsson, and L Orö, and S Rössner
[Clinical effects and tolerance of etofylline clofibrate].
January 1980, Arzneimittel-Forschung,
A G Olsson, and L Orö, and S Rössner
[Preliminary study of the effects of nicotinic-N-oxide acid causing hypolipidemia administered alone or in combination with clofibrate].
October 1977, Bollettino chimico farmaceutico,
Copied contents to your clipboard!